As explained by the NHS, sarcoidosis is a rare condition that causes small patches of swollen tissue, called granulomas, to ...

Among those treated for sarcoidosis in the year following diagnosis, 60% used steroids alone, 13% nonsteroidal immunosuppressives alone, and 27% received both. About 43% of patients with sarcoidosis ...

The increase in the global burden of interstitial lung disease (ILD) and pulmonary sarcoidosis had the greatest impact on countries with a high sociodemographic index. This recent study highlights ...

enrolled 107 patients with chronic active pulmonary sarcoidosis, a disease that can cause breathlessness, fatigue and pain. If not treated effectively, the inflammation can lead to lung scarring ...

Sarcoidosis is an inflammatory disease characterized by the formation of granulomas in one or more organs of the body. When left unchecked, chronic inflammation caused by granulomas can lead to ...

While some patients with sarcoidosis have spontaneous disease remission, others may require treatment for symptom management, organ involvement, and/or risk reduction of disease progression.

Using skin, lung, and blood samples from sarcoidosis ... Gross Professor of Dermatology and the director of Penn's Cutaneous ...

But is the disease real? Sarcoidosis is a condition where groups of cells in the immune system form small lumps called granulomas, which can appear in any organ in the body, per the U.S. National ...

The study enrolled 107 patients with pulmonary sarcoidosis considered to have chronic, active disease not well-controlled despite available therapeutic options. Patients in the study received a ...

The study enrolled 107 patients with pulmonary sarcoidosis considered to have chronic, active disease not well-controlled despite available therapeutic options. Patients in the study received a ...

Dec 3 (Reuters) - Roivant (ROIV.O), opens new tab will discontinue the development of its drug for a rare lung disease after it failed to show treatment benefits in patients in a mid-stage trial.

03, 2024 (GLOBE NEWSWIRE) -- Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced its Phase 2 study ...